Sabra Health Care REIT, Inc. (SBRA) AI Stock Analysis

Sabra Health Care REIT, Inc. manages an investment portfolio comprising 416 real estate properties totaling 41,445 beds/units across the United States and Canada. This diverse portfolio includes 279 Skilled Nursing/Transitional Care facilities, 59 leased Senior Housing communities, and 50 Senior Housing communities managed by third-party property managers. Sabra also oversees 13 Behavioral Health facilities, 15 Specialty Hospitals and Other facilities, one asset held for sale, one sales-type lease, 16 loans receivable including mortgage and construction loans, seven preferred equity investments, and one investment in an unconsolidated joint venture.

Between FY2021 and FY2025, annual revenue expanded from $569.5M to $774.6M, reflecting a 5-year revenue CAGR of 5.3%. Annual net income shifted from -$113.3M in FY2021 to $155.6M in FY2025, while gross margin declined from 75.2% to 65.0% over the same timeframe. Over the trailing twelve months, revenue reached $863.8M with a profit margin of 7.6% and an operating margin of -12.5%. In the latest quarter ended June 30, 2026, quarterly revenue rose 25.3% year-over-year, while quarterly earnings fell 5.6%.

As of June 30, 2026, Sabra held $231.6M in cash and short-term investments alongside total debt of $2.65B, yielding net debt of $2.41B and a debt-to-equity ratio of 0.96. Total assets stood at $5.51B against shareholders' equity of $2.75B and a current ratio of 43.68. Operating cash flow in FY2025 was $348.6M, matching free cash flow of $348.6M. Cash returned to shareholders included $289.5M in dividends paid during FY2025, while the 5-year share count change increased 10.9%.

At $19.34 per share, Sabra has a market capitalization of $4.94B and an enterprise value of $7.44B. The stock trades at a trailing P/E of 77.4x and a forward P/E of 32.2x, higher than the medians of 21.6x and 23.5x for its US-listed Real Estate peers. Its EV/EBITDA of 18.9x and price-to-sales ratio of 5.7x compare to peer medians of 14.7x and 3.7x. Sabra posted a 1-year return of 15.4% versus 16.8% for the S&P 500, and a 5-year return of 88.8% versus 83.0% for the index.

Sabra pays a quarterly dividend totaling an annual forward dividend of $1.20, resulting in a dividend yield of 6.20%. The company has paid dividends for 17 consecutive years, though its 5-year annualized dividend growth fell 2.3%. The dividend payout ratio stands at 114.3%, and the most recent ex-dividend date was August 14, 2026.

Analyst coverage consists of 5 Strong Buy, 1 Buy, and 10 Hold recommendations. The mean price target of $22.50 implies an upside of 16.3% over the last close of $19.34. For the fiscal year ending December 31, 2026, analysts estimate revenue of $928.0M and EPS of $0.45, representing an EPS decline of 30.2%. Sabra exceeded EPS estimates in 2 of the trailing 4 quarters, with its next earnings report scheduled for November 4, 2026.

This page is an AI-written research summary of Sabra Health Care REIT, Inc. (SBRA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SBRA income statement, SBRA balance sheet, SBRA key metrics, SBRA analyst forecast, SBRA chart. See the SBRA stock overview for the latest quote and news.